TMSB4Y

Across TCGA pan-cancer cohorts, TMSB4Y Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMSB4Y data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMSB4Y Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMSB4Y expression acts as an unfavorable survival marker.

HNSC, COAD, and PRAD are the cancer types where TMSB4Y Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.087	0.710	<.001	36	view →
COAD	OS	Median	All	0.181	0.806	.002	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMSB4Y–HNSC (DFS)

Open the HNSC breakdown →